| 000 | 01855 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517014811.0 | ||
| 264 | 0 | _c20151231 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1399-3062 | ||
| 024 | 7 |
_a10.1111/tid.12349 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStevens, D R | |
| 245 | 0 | 0 |
_aIncreased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. _h[electronic resource] |
| 260 |
_bTransplant infectious disease : an official journal of the Transplantation Society _cApr 2015 |
||
| 300 |
_a163-73 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAcademic Medical Centers |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAllografts _xvirology |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xetiology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
| 650 | 0 | 4 |
_aGraft Rejection _xprevention & control |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xsurgery |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aValganciclovir |
| 700 | 1 | _aSawinski, D | |
| 700 | 1 | _aBlumberg, E | |
| 700 | 1 | _aGalanakis, N | |
| 700 | 1 | _aBloom, R D | |
| 700 | 1 | _aTrofe-Clark, J | |
| 773 | 0 |
_tTransplant infectious disease : an official journal of the Transplantation Society _gvol. 17 _gno. 2 _gp. 163-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/tid.12349 _zAvailable from publisher's website |
| 999 |
_c24604185 _d24604185 |
||